Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

UTS2 (urotensin 2)

Written2015-01Kaifee Arman, Esra Bozgeyik, Hasan Dagli, Yusuf Ziya Igci
University of Gaziantep, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey kaifeearman786@gmail.com; gyk.esra@gmail.com; igci@gantep.edu.tr; hasandagli63@gmail.com

Abstract Review on UTS2, with data on DNA/RNA, on the protein encoded and where the gene is implicated.

Keywords UTSII, Urotensin2

(Note : for Links provided by Atlas : click)

Identity

Alias_symbol (synonym)UII
U-II
UCN2
PRO1068
Other alias
HGNC (Hugo) UTS2
LocusID (NCBI) 10911
Atlas_Id 50338
Location 1p36.23  [Link to chromosome band 1p36]
Location_base_pair Starts at 7907672 and ends at 7913104 bp from pter ( according to hg19-Feb_2009)  [Mapping UTS2.png]
Fusion genes
(updated 2016)
TESK2 (1p34.1) / UTS2 (1p36.23)UTS2 (1p36.23) / ZZEF1 (17p13.2)

DNA/RNA

 
Description The human UTS2 gene is an active cyclic heptapeptide and encodes a mature peptide. This gene is located on the reverse strand of chromosome 1. It consists of an open reading frame (ORF) having 372 nucleotides which encodes 124 amino acids. Its size is about 14.3 kDa and has an isoelectric point 7.67.
Transcription Till date three transcript variants encoding different isoforms are known for UTS2. These are transcript variant 1 (accession number NM_021995.2), transcript variant 2 (NM_006786.3) and transcript variant 3 (Ensembl version: ENST00000377516.4). Transcript variant (1) encodes 139 amino acids which is a longer preproprotein isoform. It has a transcript length of 420 bps and has 5 coding exons. Transcript variant (2) encodes 124 amino acids and is shorter preproprotein isoform. It has a transcript length of 559 bps and has 4 coding exons. The mature peptide for both transcript variants (TV1 and TV2) is known to be identical but has different amino-terminal end as compared to transcript variant 1. The two most common transcript variants (TV1 and TV2) are shown in Figure1. The third transcript variant is known to be putative protein coding. It has a transcript length of 1601 bps with a translational length of 139 residues and has a total of 7 exons with 6 coding exons. UII is most abundantly expressed in the central nervous system, for example in the brainstem and spinal cord. Apart from the CNS, UII mRNA is also expressed in the liver, kidney, cardiomyocytes, coronary and in multiple endocrine glands (Ames et al., 1999, Nothacker et al., 1999).
Pseudogene There is no pseudogene for UTS2.

Protein

 
Description Urotensin II is known to be a potent vasoactive peptide in humans and in several other animal models. It is a cyclic peptide of 12 amino acids. The cyclic region of the peptide (Cys-Phe-Trp-Lys-Tyr-Cys) of UII is evolutionary conserved but the N-terminal region of UII is highly variable (Conlon, 2000, Conlon, 2008). U-II is known to be the endogenous ligand of an orphan G-protein-coupled receptor (GPR 14). In humans, UTS2 originated from a large precursor molecule i.e prepro-U-II and is encoded by a gene on chromosome 1p36. The prepro and mature UII peptide sequences are shown in Figure2. Two splice variants of the precursor are known, one consist of124 amino acids while the other has 139 amino acids. Actually human UTS2 derived from post-translational processing of two different precursors, which are alternate splice variants (Ames et al., 1999, Coulouarn et al., 1998). Ensembl mentions a third transcript variant that is known to be putative protein coding. It has a translational length of 139 amino acids. UTS2 is having a molecular mass of approximately 14.3 kDa and has an isoelectric point 7.67.
The amino acid sequence of UTS2 is highly conserved across several vertebrates and shares structural similarity to somatostatin. Due to the structural similarities between U-II and somatostatin, it was wrongly interpreted that UTS2 shared binding sites with somatostatin. The human GPR14 (G-Protein-Coupled Receptor-14) has been found out to function as a UTS2 receptor (Ames et al., 1999, Liu et al., 1999, Mori et al., 1999, Nothacker et al., 1999). It is also known as sensory epithelium neuropeptide like receptor (SENR) (Tal et al., 1995). This receptor was later called the urotensin receptor (UTR) because of the high selectivity of GPR 14 for UTS2(Liu et al., 1999). The binding of U-II with UTR is functionally coupled to calcium mobilization.
Expression UTS2 is widely distributed and is found in a variety of different tissues. In humans it has been found in the heart (Matsushita et al., 2001), kidney (Matsushita et al., 2001, Shenouda et al., 2002, Totsune et al., 2003), liver (Totsune et al., 2003, Coulouarn et al., 1998) and in the brain and spinal cord of several other species. However the distribution of UTS2 is somewhat unusual as it is found in motor neurons of the spinal cord and motor nuclei in the brain (Coulouarn et al., 1998, Dun et al., 2001). The pre-pro UTS2 has been found to co-localize with androgen receptors in motor nuclei (Pelletier et al., 2002). Immunohistochemistry for the UII peptide reveals its presence in the neuronal cell soma of the brain and spinal cord (Ames et al., 1999, Chartrel et al., 1996, Dun et al., 2001). UTS2 is also shown to be expressed in pancreas (Totsune et al., 2003). There is very high expression of UTS2 proteins in cerebral cortex, hippocampus, lateral ventricle and cerebellum of CNS. It is also highly expressed in pancreas, duodenum, small intestine, placenta and thyroid gland. UII is moderately expressed in gall bladder, stomach, colon, kidney, testis, prostate, breast, lung, heart muscle, bronchus. It has low expression in skin, soft tissue and bone marrow. But it has not been detected in oral mucosa, adipose tissue, skeletal muscle and smooth muscle.
Localisation UTS2 has primarily extracellular localisation. This protein is found mainly in the human spinal cord generally in motoneurons.
Function UTS2 (U-II) is a well known vasoactive hormone whose action is mainly dependent on seven transmembrane spanning G-protein-coupled receptor called GPR14 (Onan et al., 2004). UII play an indispensable role in the physiological regulation of several organ systems especially within the cardiovasculature. It is known to be the most potent mammalian vasoconstrictor possessing both vasoconstrictor and vasodilatory action properties as well as profibrotic and antiapoptotic activity (Langham & Kelly, 2013). UTS2 possesses several cardiovascular actions such as potent vasoactive and cardiac inotropic and hypertropic properties (Douglas et al., 2002). It activates the G protein-coupled receptor UTS2R and thus exerts various cardiovascular effects and has a role in the pathophysiology of atherosclerosis (Segain et al., 2007). It negatively regulates blood pressure. U-II is supposed to have several behavioral activities as it occurs in the central nervous system and is widely distributed in the brain. It has been shown in studies conducted in rodents that central administration of U-II stimulates locomotion, stimulates anxiety and depressive-like conditions, provokes feeding activity and increases the duration of paradoxical sleep episodes (do Rego et al., 2008). UII also exerts a wide range of actions in other systems, such as proliferation of vascular smooth muscle cells, fibroblasts, and cancer cells (Wu et al., 2010, Lin et al., 2004, Ross et al., 2010). In addition it also increases foam cell formation, chemotaxis of inflammatory cells, and inotropic and hypertrophic effects on heart muscle, inhibits insulin release (Saez et al., 2011), modulates glomerular filtration (Langham & Kelly, 2013) and release of catecholamines and may help in the regulation of food intake and the sleep cycle (Huitron-Resendiz et al., 2005). Guidolin et al. stated that urotensin-II has an angiogenic role (Guidolin et al., 2010). Furthermore endogenous urotensin II has a role in erectile functioning by selectively modulating its mechanism through eNOS (Bianca et al., 2012).
Homology UTS2 is a partial homologue of somatostatin and shares structural similarity to somatostatin. It was also demonstrated that both rat and mouse homologs share sequence homology with human prepro UTS2 (Coulouarn et al., 1999). All the known homologs of UTS2 are known to share a highly conserved cyclic region in the peptide which predicts that this region has a functional significance.

Mutations

Note Different genetic polymorphisms in UTS2 and their association with diseases:
Several single nucleotide polymorphisms (SNPs) in genes encoding for urotensin II (UTS2) are known and have been well studied. According to the US National Center for Biotechnology Information (NCBI) database, over 60 single nucleotide polymorphisms (SNP) have been noted in the human UTS2 gene. Three of these SNP show amino acid changes in the UTS2 gene sequence. The well known SNP, 143G>A (T21M, rs228648) in the UTS2 gene is found to be associated with type 2 diabetes in Han people residing in northern China (Suguro et al., 2007, Zhu et al., 2002) while the other SNP, 3836C>T (S89N, rs2890565) has association with higher plasma insulin level, insulin resistance, and susceptibility of developing type 2 diabetes in Hong Kong Chinese and Japanese (Ong et al., 2006, Suzuki et al., 2004, Wenyi et al., 2003). The SNP, 3836C>T is supposed to be a functional SNP as it has association with higher plasma UTS2 level (Ong et al., 2006). Recently it has been found that Thr21Met (T21M) polymorphisms of the UTS2 gene were associated with higher risk of developing Behcet's disease as well as Systemic Sclerosis (Oztuzcu et al., 2013, Pehlivan et al., 2012). Both Thr21Met (T21M) and Ser89Asn (S89N) polymorphisms of the UTS2 gene have been found to be pathologically associated with the risk of developing diabetes and Diabetic Retinopathy (Okumus et al., 2012). The exchange of serine instead of asparagine at amino acid position 89 changes the structure of UTS2. Due to this, mutation at this particular point is likely to form immature UII peptide that might cause several pathological conditions (Okumus et al., 2012).

Implicated in

Note
  
Entity Breast cancer
Note In a recent study, Balakan et al. (2014) found that U-II and UTR mRNA is being expressed in the breast tissue and breast cancer tissue. Consequently they found an association of UTS2 with menopausal status, and extra-nodal and lymphatic invasion in breast cancer patients (Balakan et al., 2014).
  
  
Entity Atherosclerosis
Note Atherosclerosis is vascular inflammation which is chronic in nature and results in the deposition of lipid and leucocyte in the arterial wall (Loirand et al., 2008). In hypertensive patients, plasma U-II level is found to be positively correlated with carotid atherosclerosis (Suguro et al., 2007) as well as in patients with coronary artery isease (Heringlake et al., 2004)
  
  
Entity Metabolic syndrome
Note UTS2 is considered to give rise to the metabolic syndrome and its components, like hyperglycemia, hypertension, insulin resistance and inflammation. It has a role in inflammation by effecting ingestive behavior. Plasma UTS2 level has a positive correlation with systolic blood pressure and insulin resistance (Cheung et al., 2004, Ong et al., 2006, Suguro et al., 2007). The two well known disorders i.e hypertension and insulin resistance are known to occur together as components of the metabolic syndrome ( Reaven G.M, 1988).
  
  
Entity Behcet's disease
Note Oztuzcu et al. (2013) described that Thr21Met (T21M) polymorphisms of the UTS2 gene is known to be associated with Behcet's disease (BD) in Turkish population (Oztuzcu et al., 2013).
  
  
Entity Diabetes Mellitus and Diabetic Retinopathy
Note An association between Thr21Met and Ser89Asn polymorphisms of the UTS2 gene, Diabetes Mellitus and Diabetic Retinopathy has been found by Okumus et al. (Okumus et al., 2012).
  
  
Entity Systemic Sclerosis
Note Pehlivan et al. (2011) suggested that Thr21Met, but not Ser89Asn has an important role in the development of Systemic Sclerosis, and a powerful indicator of severe skin and lung involvement in patients with Systemic Sclerosis (Pehlivan et al., 2012).
  
  
Entity Renal disease
Note Totsune et al. (2001) reported higher levels of plasma UTS2 i.e an increase in three fold and two fold in patients with renal dysfunction, with and without dialysis respectively as compared with healthy control (Totsune et al., 2001). This indicated a role of UTS2 in renal function.
  
  
Entity Congestive Heart Failure
Note It has been found that myocardial UII is significantly expressed in heart samples taken from patients with congestive heart failure as compared to controls, which was inversely correlated with ejection fraction (Douglas et al., 2002).
  
  
Entity Type 2 diabetes mellitus
Note Wenyi et al. reported the association of S89N polymorphism in the UTS2 with the development of Type 2 diabetes, via insulin sensitivity, in Japanese subjects (Wenyi et al., 2003).
  
  
Entity Pre-eclampsia.
Note ElSharkawy et al. showed the elevation of UTS2 in the serum of PE patients which could be correlated to the severity and/or progression of the disease. The UTS2 genotype frequencies between patients and control groups showed a significant difference, which implies a potential benefit for UTS2 gene or level in serum as a diagnostic or prognostic indicator in pre-eclampsia (ElSharkawy et al., 2014). Endothelial nitric oxide synthase (eNOS) (Glu298Asp) and UTS2 (UTS2 S89N) gene polymorphisms are promising markers for early prediction of preeclampsia in Egyptian females (El-Sherbiny et al., 2013).
  
  
Entity Schizophrenia
Note Higher UTS2 expression was found in schizophrenia patients suggesting that UTS2 level may be a probable candidate related to the pathology of the disease (Bulbul et al., 2014).
  

To be noted

Acknowledgments: Kaifee Arman is recipient of Graduate Scholarship from TUBITAK under the program 2215-Graduate Scholarship Program for International Students

Bibliography

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA
Nature 1999 Sep 16;401(6750):282-6
PMID 10499587
 
The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer
Balakan O, Kalender ME, Suner A, Cengiz B, Oztuzcu S, Bayraktar R, Borazan E, Babacan T, Camci C
Med Sci Monit 2014 Aug 12;20:1419-25
PMID 25112588
 
Endogenous urotensin II selectively modulates erectile function through eNOS
Bianca Rd, Mitidieri E, Fusco F, D'Aiuto E, Grieco P, Novellino E, Imbimbo C, Mirone V, Cirino G, Sorrentino R
PLoS One 2012;7(2):e31019
PMID 22319601
 
New molecule in the etiology of schizophrenia: urotensin II
Bulbul F, Alpak G, Unal A, Copoglu US, Orkmez M, Virit O, Tarkcioglu M, Savas HA
Psychiatry Clin Neurosci 2014 Feb;68(2):133-6
PMID 24552634
 
Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization
Chartrel N, Conlon JM, Collin F, Braun B, Waugh D, Vallarino M, Lahrichi SL, Rivier JE, Vaudry H
J Comp Neurol 1996 Jan 8;364(2):324-39
PMID 8788253
 
Plasma concentration of urotensin II is raised in hypertension
Cheung BM, Leung R, Man YB, Wong LY
J Hypertens 2004 Jul;22(7):1341-4
PMID 15201550
 
Liberation of urotensin II from the teleost urophysis: an historical overview
Conlon JM
Peptides 2008 May;29(5):651-7
PMID 17544546
 
Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord
Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H
Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15803-8
PMID 9861051
 
Congestive heart failure and expression of myocardial urotensin II
Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A
Lancet 2002 Jun 8;359(9322):1990-7
PMID 12076554
 
Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat
Dun SL, Brailoiu GC, Yang J, Chang JK, Dun NJ
Neurosci Lett 2001 Jun 1;305(1):9-12
PMID 11356295
 
Endothelial nitric oxide synthase (eNOS) (Glu298Asp) and urotensin II (UTS2 S89N) gene polymorphisms in preeclampsia: prediction and correlation with severity in Egyptian females
El-Sherbiny WS, Nasr AS, Soliman A
Hypertens Pregnancy 2013 Aug;32(3):292-303
PMID 23905608
 
Study of urotensin II gene and serum levels in relation to pre-eclampsia
ElSharkawy RM, Moiety FM, Hegab HM
Clin Exp Obstet Gynecol 2014;41(4):394-8
PMID 25134283
 
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
JAMA 2001 May 16;285(19):2486-97
PMID 11368702
 
Urotensin-II as an angiogenic factor
Guidolin D, Albertin G, Ribatti D
Peptides 2010 Jun;31(6):1219-24
PMID 20346384
 
The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease
Heringlake M, Kox T, Uzun O, Will B, Bahlmann L, Klaus S, Eleftheriadis S, Armbruster FP, Franz N, Kraatz E
Regul Pept 2004 Sep 15;121(1-3):129-36
PMID 15256283
 
Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons
Huitron-Resendiz S, Kristensen MP, Sánchez-Alavez M, Clark SD, Grupke SL, Tyler C, Suzuki C, Nothacker HP, Civelli O, Criado JR, Henriksen SJ, Leonard CS, de Lecea L
J Neurosci 2005 Jun 8;25(23):5465-74
PMID 15944374
 
Urotensin II and the kidney
Langham RG, Kelly DJ
Curr Opin Nephrol Hypertens 2013 Jan;22(1):107-12
PMID 23197158
 
Role of ERK and Rho kinase pathways in central pressor action of urotensin II
Lin Y, Matsumura K, Tsuchihashi T, Fukuhara M, Fujii K, Iida M
J Hypertens 2004 May;22(5):983-8
PMID 15097239
 
Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14
Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT
Biochem Biophys Res Commun 1999 Dec 9;266(1):174-8
PMID 10581185
 
Urotensin II and atherosclerosis
Loirand G, Rolli-Derkinderen M, Pacaud P
Peptides 2008 May;29(5):778-82
PMID 17933432
 
Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues
Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y
J Hypertens 2001 Dec;19(12):2185-90
PMID 11725162
 
Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)
Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, Kikuchi K, Shintani Y, Kurokawa T, Onda H, Nishimura O, Fujino M
Biochem Biophys Res Commun 1999 Nov;265(1):123-9
PMID 10548501
 
Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction
Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP, Civelli O
Nat Cell Biol 1999 Oct;1(6):383-5
PMID 10559967
 
Association between Thr21Met and Ser89Asn polymorphisms of the urotensin-II (UTS2) gene, diabetes mellitus, and diabetic retinopathy
Okumus S, Igci YZ, Taskin T, Oztuzcu S, Gurler B, Eslik Z, Gogebakan B, Coskun E, Erbagci I, Demiryurek S, Cengiz B, Demiryurek AT
Curr Eye Res 2012 Oct;37(10):921-9
PMID 22587369
 
Urotensin II: the old kid in town
Onan D, Hannan RD, Thomas WG
Trends Endocrinol Metab 2004 May-Jun;15(4):175-82
PMID 15109617
 
Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance
Ong KL, Wong LY, Man YB, Leung RY, Song YQ, Lam KS, Cheung BM
Peptides 2006 Jul;27(7):1659-67
PMID 16597476
 
Thr21Met (T21M) but not Ser89Asn (S89N) polymorphisms of the urotensin-II (UTS-II) gene are associated with Behcet's disease (BD)
Oztuzcu S, Ulasli M, Pehlivan Y, Cevik MÖ, Cengiz B, Gogebakan B, Igci YZ, Okumus S, Arslan A, Onat AM
Peptides 2013 Apr;42:97-100
PMID 23333481
 
Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II gene and systemic sclerosis
Pehlivan Y, Gogebakan B, Oztuzcu S, Ozgen M, Cetin GY, Bayraktar R, Cengiz B, Kisacik B, Koca SS, Donmez S, Sayarlioglu M, Demiryurek AT, Onat AM
J Rheumatol 2012 Jan;39(1):106-11
PMID 22045841
 
Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord
Pelletier G, Lihrmann I, Vaudry H
Neuroscience 2002;115(2):525-32
PMID 12421619
 
Banting lecture 1988
Reaven GM
Role of insulin resistance in human disease Diabetes
PMID 3056758
 
Role of urotensin II in health and disease
Ross B, McKendy K, Giaid A
Am J Physiol Regul Integr Comp Physiol 2010 May;298(5):R1156-72
PMID 20421634
 
Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance
Sáez ME, Smani T, Ramírez-Lorca R, Díaz I, Serrano-Ríos M, Ruiz A, Ordoñez A
PLoS One 2011 Apr 29;6(4):e19327
PMID 21559414
 
Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes
Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Blétière D, Loirand G, Pacaud P
J Immunol 2007 Jul 15;179(2):901-9
PMID 17617581
 
Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma
Shenouda A, Douglas SA, Ohlstein EH, Giaid A
J Histochem Cytochem 2002 Jul;50(7):885-9
PMID 12070267
 
Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension
Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, Adachi M
Am J Hypertens 2007 Feb;20(2):211-7
PMID 17261470
 
Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese
Suzuki S, Wenyi Z, Hirai M, Hinokio Y, Suzuki C, Yamada T, Yoshizumi S, Suzuki M, Tanizawa Y, Matsutani A, Oka Y
Peptides 2004 Oct;25(10):1803-8
PMID 15476949
 
A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia
Tal M, Ammar DA, Karpuj M, Krizhanovsky V, Naim M, Thompson DA
Biochem Biophys Res Commun 1995 Apr 17;209(2):752-9
PMID 7733947
 
Role of urotensin II in patients on dialysis
Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O
Lancet 2001 Sep 8;358(9284):810-1
PMID 11564491
 
Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects
Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J, Oka Y
Diabetologia 2003 Jul;46(7):972-6
PMID 12830381
 
Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo
Wu YQ, Song Z, Zhou CH, Xing SH, Pei DS, Zheng JN
Oncol Rep 2010 Nov;24(5):1179-84
PMID 20878108
 
[The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population]
Zhu F, Ji L, Luo B
Zhonghua Yi Xue Za Zhi 2002 Nov 10;82(21):1473-5
PMID 12509909
 
Behavioral actions of urotensin-II
do Rego JC, Leprince J, Scalbert E, Vaudry H, Costentin J
Peptides 2008 May;29(5):838-44
PMID 18294732
 

Citation

This paper should be referenced as such :
Arman K, Bozgeyik E, I Dagli H, Igci YZ
UTS2 (urotensin 2);
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Genes/UTS2ID50338ch1p36.html


External links

Nomenclature
HGNC (Hugo)UTS2   12636
Cards
AtlasUTS2ID50338ch1p36
Entrez_Gene (NCBI)UTS2  10911  urotensin 2
AliasesPRO1068; U-II; UCN2; UII
GeneCards (Weizmann)UTS2
Ensembl hg19 (Hinxton)ENSG00000049247 [Gene_View]  chr1:7907672-7913104 [Contig_View]  UTS2 [Vega]
Ensembl hg38 (Hinxton)ENSG00000049247 [Gene_View]  chr1:7907672-7913104 [Contig_View]  UTS2 [Vega]
ICGC DataPortalENSG00000049247
TCGA cBioPortalUTS2
AceView (NCBI)UTS2
Genatlas (Paris)UTS2
WikiGenes10911
SOURCE (Princeton)UTS2
Genetics Home Reference (NIH)UTS2
Genomic and cartography
GoldenPath hg19 (UCSC)UTS2  -     chr1:7907672-7913104 -  1p36   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)UTS2  -     1p36   [Description]    (hg38-Dec_2013)
EnsemblUTS2 - 1p36 [CytoView hg19]  UTS2 - 1p36 [CytoView hg38]
Mapping of homologs : NCBIUTS2 [Mapview hg19]  UTS2 [Mapview hg38]
OMIM604097   
Gene and transcription
Genbank (Entrez)AF104118 AF140630 AY358375 BC025776 BC126443
RefSeq transcript (Entrez)NM_006786 NM_021995
RefSeq genomic (Entrez)NC_000001 NC_018912 NT_032977 NW_004929289
Consensus coding sequences : CCDS (NCBI)UTS2
Cluster EST : UnigeneHs.715862 [ NCBI ]
CGAP (NCI)Hs.715862
Alternative Splicing GalleryENSG00000049247
Gene ExpressionUTS2 [ NCBI-GEO ]   UTS2 [ EBI - ARRAY_EXPRESS ]   UTS2 [ SEEK ]   UTS2 [ MEM ]
Gene Expression Viewer (FireBrowse)UTS2 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)10911
GTEX Portal (Tissue expression)UTS2
Protein : pattern, domain, 3D structure
UniProt/SwissProtO95399   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtO95399  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProO95399
Splice isoforms : SwissVarO95399
PhosPhoSitePlusO95399
Domaine pattern : Prosite (Expaxy)UROTENSIN_II (PS00984)   
Domains : Interpro (EBI)Urotensin_II   
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)UTS2
DMDM Disease mutations10911
Blocks (Seattle)UTS2
SuperfamilyO95399
Human Protein AtlasENSG00000049247
Peptide AtlasO95399
HPRD04976
IPIIPI00030122   IPI00419728   IPI00552784   
Protein Interaction databases
DIP (DOE-UCLA)O95399
IntAct (EBI)O95399
FunCoupENSG00000049247
BioGRIDUTS2
STRING (EMBL)UTS2
ZODIACUTS2
Ontologies - Pathways
QuickGOO95399
Ontology : AmiGOresponse to hypoxia  negative regulation of glomerular filtration  receptor binding  hormone activity  extracellular region  extracellular space  cytosol  muscle contraction  positive regulation of cytosolic calcium ion concentration  synaptic transmission  regulation of blood pressure  negative regulation of heart rate  positive regulation of heart rate  positive regulation of fibroblast migration  positive regulation of circadian sleep/wake cycle, wakefulness  positive regulation of synaptic transmission, cholinergic  positive regulation of collagen biosynthetic process  response to testosterone  negative regulation of urine volume  negative regulation of renal sodium excretion  response to drug  positive regulation of cell differentiation  positive regulation of angiogenesis  negative regulation of blood pressure  positive regulation of blood pressure  positive regulation of vasodilation  positive regulation of circadian sleep/wake cycle, REM sleep  negative regulation of insulin secretion  positive regulation of fibroblast proliferation  
Ontology : EGO-EBIresponse to hypoxia  negative regulation of glomerular filtration  receptor binding  hormone activity  extracellular region  extracellular space  cytosol  muscle contraction  positive regulation of cytosolic calcium ion concentration  synaptic transmission  regulation of blood pressure  negative regulation of heart rate  positive regulation of heart rate  positive regulation of fibroblast migration  positive regulation of circadian sleep/wake cycle, wakefulness  positive regulation of synaptic transmission, cholinergic  positive regulation of collagen biosynthetic process  response to testosterone  negative regulation of urine volume  negative regulation of renal sodium excretion  response to drug  positive regulation of cell differentiation  positive regulation of angiogenesis  negative regulation of blood pressure  positive regulation of blood pressure  positive regulation of vasodilation  positive regulation of circadian sleep/wake cycle, REM sleep  negative regulation of insulin secretion  positive regulation of fibroblast proliferation  
REACTOMEO95399 [protein]
REACTOME Pathways375276 [pathway]   416476 [pathway]   
NDEx NetworkUTS2
Atlas of Cancer Signalling NetworkUTS2
Wikipedia pathwaysUTS2
Orthology - Evolution
OrthoDB10911
GeneTree (enSembl)ENSG00000049247
Phylogenetic Trees/Animal Genes : TreeFamUTS2
HOVERGENO95399
HOGENOMO95399
Homologs : HomoloGeneUTS2
Homology/Alignments : Family Browser (UCSC)UTS2
Gene fusions - Rearrangements
Fusion : MitelmanTESK2/UTS2 [1p34.1/1p36.23]  [t(1;1)(p34;p36)]  
Fusion: TCGATESK2 1p34.1 UTS2 1p36.23 BRCA
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerUTS2 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)UTS2
dbVarUTS2
ClinVarUTS2
1000_GenomesUTS2 
Exome Variant ServerUTS2
ExAC (Exome Aggregation Consortium)UTS2 (select the gene name)
Genetic variants : HAPMAP10911
Genomic Variants (DGV)UTS2 [DGVbeta]
DECIPHER (Syndromes)1:7907672-7913104  ENSG00000049247
CONAN: Copy Number AnalysisUTS2 
Mutations
ICGC Data PortalUTS2 
TCGA Data PortalUTS2 
Broad Tumor PortalUTS2
OASIS PortalUTS2 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICUTS2  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDUTS2
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch UTS2
DgiDB (Drug Gene Interaction Database)UTS2
DoCM (Curated mutations)UTS2 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)UTS2 (select a term)
intoGenUTS2
NCG5 (London)UTS2
Cancer3DUTS2(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM604097   
Orphanet
MedgenUTS2
Genetic Testing Registry UTS2
NextProtO95399 [Medical]
TSGene10911
GENETestsUTS2
Huge Navigator UTS2 [HugePedia]
snp3D : Map Gene to Disease10911
BioCentury BCIQUTS2
ClinGenUTS2
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD10911
Chemical/Pharm GKB GenePA37261
Clinical trialUTS2
Miscellaneous
canSAR (ICR)UTS2 (select the gene name)
Probes
Litterature
PubMed90 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineUTS2
EVEXUTS2
GoPubMedUTS2
iHOPUTS2
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:51:43 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.